Physician profile
Bernard Philippe
NPI 1548648561
$6,059.10
in general payments reported to CMS, 2019-2025
49 companies · $660 in 2025
The $660 reported for 2025 was more than what 88% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,280 · 2020: $233 · 2021: $137 · 2022: $802 · 2023: $1,642 · 2024: $1,304 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,606.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $777.25 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $498.69 | 2019-2025 | Airsupra, Farxiga, Evusheld |
| Abbvie INC. | $468.80 | 2019-2025 | |
| Novo Nordisk INC | $415.84 | 2019-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $364.73 | 2019-2023 | Freestyle Libre 2 |
| Pfizer INC. | $342.31 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $271.42 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $251.21 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.05 | 2019-2025 | Jardiance |
| Sunovion Pharmaceuticals INC. | $160.41 | 2019-2020 | |
| Allergan, INC. | $159.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $149.60 | 2019-2023 | |
| Amgen INC. | $145.04 | 2019-2025 | Repatha, Otezla, Otezla |
| Otsuka America Pharmaceutical, INC. | $144.14 | 2022-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $142.04 | 2022-2024 | Ingrezza, Ongentys |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $137.21 | 2022-2024 | Austedo Xr, Austedo |
| Idorsia Pharmaceuticals US INC | $129.45 | 2023 | Quviviq |
| Astellas Pharma US INC | $117.81 | 2019 | |
| Lucid Diagnostics INC. | $101.79 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $96.10 | 2022-2024 | Xarelto |
| Dexcom, INC. | $85.11 | 2023-2024 | Dexcom G6 Transmitter |
| Ucb, INC. | $82.58 | 2022-2023 | Nayzilam, Briviact |
| Medtronic, INC. | $70.75 | 2025 | Abre |
| Merck Sharp & Dohme LLC | $62.72 | 2019-2023 | Verquvo, Januvia, Belsomra |
| Lilly USA, LLC | $52.29 | 2023-2025 | Mounjaro, Zepbound, Lyumjev |
| Scilex Pharmaceuticals INC. | $50.64 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $47.38 | 2019-2025 | |
| Insmed, INC. | $44.86 | 2020-2023 | Arikayce |
| Corium, LLC | $42.88 | 2022-2023 | Adlarity |
| Phathom Pharmaceuticals, INC. | $41.32 | 2024 | Voquezna |
| Mylan Specialty L.P. | $36.76 | 2019-2023 | Yupelri |
| Shield Therapeutics INC | $32.96 | 2024 | |
| Acadia Pharmaceuticals INC | $29.48 | 2019 | |
| Boston Scientific Corporation | $27.60 | 2024 | Watchman Access System |
| Viiv Healthcare Company | $24.91 | 2023 | Dovato |
| Si-Bone, INC. | $24.76 | 2024 | |
| Corcept Therapeutics | $23.19 | 2024 | Korlym |
| Smith+Nephew, INC. | $21.89 | 2019 | |
| Portola Pharmaceuticals, LLC | $20.32 | 2020 | |
| Eisai INC. | $19.85 | 2020 | |
| Amneal Pharmaceuticals LLC | $19.58 | 2023 | Lyvispah |
| Amarin Pharma, INC. | $18.59 | 2019 | |
| Renalytix Ai, INC. | $17.38 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Lifescan, INC. | $17.04 | 2023 | |
| Global Blood Therapeutics, INC. | $15.23 | 2022 | |
| Vivus LLC | $13.53 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.32 | 2024 | Nuzyra |
| Sanofi Pasteur INC. | $12.49 | 2019 | |
| Sumitomo Pharma America, INC. | $9.89 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Philippe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.